AXL and metabolic dysfunction-associated steatohepatitis: The findings highlight the relevance of the cleaved extracellular domain of the AXL receptor, sAXL, as an early biomarker of MASLD/MASH, before the onset of histological fibrosis, and support the potential therapeutic use of AXL inhibition in preventing disease progression.